Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia.
Flupirtine as Oral Treatment in Multiple Sclerosis (FLORIMS)
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
24th Biennial Meeting ISN/ASN 2013
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Regulatory T Cells Contribute to the Inhibition of Radiation-Induced Acute Lung Inflammation via Bee Venom Phospholipase A₂ in Mice.
PML in a patient treated with fumaric acid.
Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice - comparison of 1.5 and 3 Tesla magnetic resonance imaging.
FDA approves Genzyme’s AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing multiple sclerosis
Headache in relapse and remission phases of multiple sclerosis: A case-control study.
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx
Emerging oral agents for multiple sclerosis.
Episode 6 with Dr. Jeffrey Dunn on biomarkers and personalized medicine
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Neuroimmunology: Clostridium-reactive T cells are implicated in the pathogenesis of neuromyelitis optica.
A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
Genpharm and Genzyme Aubagio ® agreement for the MENA region
Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.
IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study.
Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.
Regulation of B cell function by the immunosuppressive agent leflunomide.
Long-term effectiveness of glatiramer acetate in clinical practice conditions.
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis

Pages